<div id="readability-page-1"><p>Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) Director Wendell Wierenga sold 20,000 shares of Cytokinetics stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $66.14, for a total value of $1,322,800.00. Following the sale, the director directly owned 32,444 shares in the company, valued at $2,145,846.16. This trade represents a 38.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.</p><ul><li>Analysts Think There's Still Time to Get in on Edgewise, Up 332%</li></ul><p>Wendell Wierenga also recently made the following trade(s): </p><ul><li>On Monday, October 27th, Wendell Wierenga sold 4,375 shares of Cytokinetics stock. The stock was sold at an average price of $58.68, for a total value of $256,725.00. </li></ul><h2>Cytokinetics Stock Performance</h2><p>CYTK traded down $2.31 during trading on Tuesday, reaching $63.29. 2,911,496 shares of the company traded hands, compared to its average volume of 1,932,222. Cytokinetics, Incorporated has a 12-month low of $29.31 and a 12-month high of $70.98. The firm has a fifty day simple moving average of $62.83 and a 200 day simple moving average of $48.88. The company has a market cap of $7.74 billion, a P/E ratio of -10.06 and a beta of 0.58. </p><ul><li>Want Diversified Upside in Biotechnology? Check out LABU</li></ul><p>Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) EPS for the quarter, topping the consensus estimate of ($1.59) by $0.05. The company had revenue of $1.94 million during the quarter, compared to analysts' expectations of $6.05 million. During the same period last year, the firm posted ($1.36) EPS. Cytokinetics's quarterly revenue was up 318.1% compared to the same quarter last year.  As a group, sell-side analysts expect that  Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year. </p><h2>Analyst Ratings Changes</h2><p>A number of research analysts have recently weighed in on the company. HC Wainwright raised their price objective on Cytokinetics from $120.00 to $136.00 and gave the company a &#34;buy&#34; rating in a research report on Monday. Bank of America raised their price target on Cytokinetics from $52.00 to $56.00 and gave the company a &#34;neutral&#34; rating in a report on Thursday, October 2nd. Leerink Partners  set a $83.00 price objective on Cytokinetics in a research note on Monday. Wall Street Zen downgraded Cytokinetics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 8th. Finally, Needham &amp; Company LLC raised their target price on shares of Cytokinetics from $72.00 to $84.00 and gave the company a &#34;buy&#34; rating in a report on Monday. Fifteen equities research analysts have rated the stock with a Buy rating, three have issued  a Hold rating and one  has issued  a Sell rating to the stock. According to MarketBeat, Cytokinetics currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $83.61.</p><p><b>Read Our Latest Stock Report on Cytokinetics</b></p><h2>Institutional Inflows and Outflows</h2><p>Several institutional investors and hedge funds have recently bought and sold shares of the company. Hudson Bay Capital Management LP boosted its stake in  Cytokinetics by 15.4% during the third quarter. Hudson Bay Capital Management LP now owns 182,131 shares of the biopharmaceutical company's stock worth $10,010,000 after buying an additional 24,345 shares during the period.  Swiss Life Asset Management Ltd bought a new stake in shares of  Cytokinetics in the 3rd quarter worth about $283,000.  CIBC Private Wealth Group LLC lifted its holdings in shares of  Cytokinetics by 8.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 3,484 shares of the biopharmaceutical company's stock worth $191,000 after acquiring an additional 261 shares during the last quarter.  CIBC Bancorp USA Inc. purchased a new position in shares of  Cytokinetics during the 3rd quarter worth about $684,000.  Finally, Coldstream Capital Management Inc. bought a new position in  Cytokinetics during the 3rd quarter valued at about $261,000. </p><h2>Cytokinetics News Summary</h2><p>Here are the key news stories impacting Cytokinetics this week:</p><ul>   <li><span>Positive Sentiment: </span>FDA approval of MYQORZO turns Cytokinetics into a commercial-stage company, creating a new cardiology revenue stream and shifting investor focus from pipeline value to product sales growth. Read More.</li>    <li><span>Positive Sentiment: </span>Several banks raised price targets and reiterated buy/outperform views (Barclays, Morgan Stanley, Needham, Citizens JMP, BofA), signaling refreshed analyst conviction and giving investors upward valuation anchors. Representative articles: Read More., Read More., Read More.</li>    <li><span>Positive Sentiment: </span>Analyst commentary highlights MYQORZO’s label advantages (flexible dosing) versus the incumbent (Camzyos), which management believes can drive &gt;50% physician preference and mid‑high 20% category penetration by end‑2026 — supporting a multi‑year sales ramp if adoption meets targets. Read More.</li>    <li><span>Positive Sentiment: </span>Unusually large call‑option activity (5,619 calls bought, roughly +103% vs. normal) indicates speculative/hedged bullish positioning ahead of/after the approval news. (Market options flow reported 12/22.)</li>    <li><span>Neutral Sentiment: </span>Company management publicly discussed the FDA approval and commercial plans (transcript coverage available) — useful for modeling uptake timing and launch costs but not an immediate revenue read. Read More.</li>    <li><span>Negative Sentiment: </span>Analyst writeups note adoption may be gradual and could rely on assistance programs to reach penetration targets, which introduces execution and margin risk during the launch phase. Read More.</li> </ul><h2>Cytokinetics Company Profile</h2> (Get Free Report)<p>Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.  </p><p>The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Cytokinetics</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cytokinetics Right Now?</h2><p>Before you consider Cytokinetics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytokinetics wasn't on the list.</p><p>While Cytokinetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CYTK

<p>Cytokinetics Director Wendell Wierenga sold 20,000 shares for $1,322,800, reducing his ownership by 38.14%. The sale was disclosed in an SEC filing. The company's stock performance and recent earnings were also highlighted, with analysts providing mixed ratings and price targets. Institutional investors have been active in buying and selling shares. Recent FDA approval of MYQORZO has positively impacted the company's outlook.</p>

Cytokinetics (NASDAQ:CYTK) Director Sells $1,322,800.00 in Stock